Shuttle Pharmaceuticals Holdings, Inc. (SHPH)
Market Cap | 14.84M |
Revenue (ttm) | n/a |
Net Income (ttm) | -3.37M |
Shares Out | 13.80M |
EPS (ttm) | -0.29 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 260,683 |
Open | 1.14 |
Previous Close | 1.11 |
Day's Range | 1.07 - 1.15 |
52-Week Range | 1.02 - 126.26 |
Beta | n/a |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 25, 2023 |
About SHPH
Shuttle Pharmaceuticals Holdings, Inc., through its subsidiary, Shuttle Pharmaceuticals, Inc., focuses on the discovery, development, and commercialization of drugs for sensitizing cancers to radiation therapy. Its products in clinical stage include Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and soft tissue sarcomas; and Doranidazole, an injectable hypoxic cell radiation sensitizer for treatment of pancreatic, lung, and liver cancers. The company was founded in 2012 and is based in Rockville, Maryland. [Read more]
Full Company ProfileFinancial Performance
Financial StatementsNews

Shuttle Pharmaceuticals Provides First Quarter 2023 Corporate Update
ROCKVILLE, Md. , May 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

Shuttle Pharmaceuticals to Participate in the Lytham Partners Spring 2023 Investor Conference
ROCKVILLE, Md. , May 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes fo...

Shuttle Pharmaceuticals Enters Research Agreement with Georgetown University for Testing of Small Molecule Radiation Sensitizers and Immune Activation Candidates
ROCKVILLE, Md. , March 22, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outco...

Shuttle Pharmaceuticals Provides Fiscal Year 2022 Corporate Update
ROCKVILLE, Md. , March 15, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving outcomes ...

Shuttle Pharmaceuticals Engages UI Pharmaceuticals for Formulation and Clinical Batch Manufacture of Ropidoxuridine for Brain Tumor Clinical Trial
ROCKVILLE, Md. , March 9, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Expands Laboratory Space to Advance Drug Development Pipeline and Diagnostic Capabilities
ROCKVILLE, Md. , Feb. 23, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals to Present at Lytham Partners Investor Select Conference on January 31
ROCKVILLE, Md. , Jan. 26, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals to Ring Nasdaq Opening Bell on Wednesday, January 18, 2023
ROCKVILLE, Md. , Jan. 17, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Announces Private Placement of $4.3 Million of Senior Secured Convertible Note and Warrants
ROCKVILLE, Md. , Jan. 12, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Manuscript Published in Cancer Research Communications
ROCKVILLE, Md. , Jan. 10, 2023 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Provides Third Quarter 2022 Corporate Update
ROCKVILLE, Md. , Nov. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Engages Theradex Oncology in Preparation for Clinical Study
ROCKVILLE, Md. , Nov. 3, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcome...

Shuttle Pharmaceuticals Appoints Bette Jacobs to its Board of Directors
ROCKVILLE, Md. , Nov. 1, 2022 /PRNewswire/ --Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcomes...

Shuttle Pharmaceuticals Enters into Manufacturing Agreement for Ropidoxuridine
Agreement to help advance lead clinical sensitizer drug candidate ROCKVILLE, Md. , Sept. 20, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development sta...
Shuttle Pharmaceuticals ($SHPH) Awarded New HDAC Inhibitor Patents for Cancer Treatment
Shuttle Pharmaceuticals ($SHPH), has announced that it has been awarded patents in the U.S. and Hong Kong for its radiation sensitizing HDAC inhibitor technology platform, which is focused on reducing...

Shuttle Pharmaceuticals Awarded New HDAC Inhibitor Patents for Cancer Treatment
Company awarded patents in the U.S. and Hong Kong ROCKVILLE, Md. , Sept. 15, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pha...

Shuttle Pharmaceuticals Announces Closing of Initial Public Offering
ROCKVILLE, Md. , Sept. 6, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Commences Trading on Nasdaq Under Ticker Symbol "SHPH"
Shuttle Pharma's platform of sensitizers are designed to address the urgent clinical need to improve the outcomes of cancer patients treated with radiation therapy while reducing side effects ROCKVILL...

Shuttle Pharmaceuticals Announces Pricing of Initial Public Offering
ROCKVILLE, Md. , Aug. 30, 2022 /PRNewswire/ -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), a discovery and development stage specialty pharmaceutical company focused on improving the outcom...

Shuttle Pharmaceuticals Holdings IPO Registration Document (S-1)
Shuttle Pharmaceuticals Holdings has filed to go public with an IPO on the NASDAQ